Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
INmune Bio 2.174M share Spot Secondary priced at $10.00 » 09:16
07/16/20
07/16
09:16
07/16/20
09:16
INMB

INmune Bio

$13.15 /

-2.65 (-16.77%)

BTIG acted as sole book…

BTIG acted as sole book running manager for the offering.

ShowHide Related Items >><<
INMB INmune Bio
$13.15 /

-2.65 (-16.77%)

INMB INmune Bio
$13.15 /

-2.65 (-16.77%)

07/14/20 Roth Capital
INmune Bio price target raised to $26 from $13 at Roth Capital
03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
INMB INmune Bio
$13.15 /

-2.65 (-16.77%)

  • 16
    Jul
INMB INmune Bio
$13.15 /

-2.65 (-16.77%)

Syndicate
INmune Bio announces offering of common stock, no amount given » 16:12
07/15/20
07/15
16:12
07/15/20
16:12
INMB

INmune Bio

$13.11 /

-2.69 (-17.03%)

INmune Bio announced that…

INmune Bio announced that it has commenced an underwritten public offering of shares of common stock. INmune Bio intends to use the net proceeds from this offering for working capital and general corporate purposes and to advance the development of its product candidates and expand its pipeline. BTIG is acting as the sole book-running manager for the offering.

ShowHide Related Items >><<
INMB INmune Bio
$13.11 /

-2.69 (-17.03%)

INMB INmune Bio
$13.11 /

-2.69 (-17.03%)

07/14/20 Roth Capital
INmune Bio price target raised to $26 from $13 at Roth Capital
03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
INMB INmune Bio
$13.11 /

-2.69 (-17.03%)

INMB INmune Bio
$13.11 /

-2.69 (-17.03%)

Recommendations
INmune Bio price target raised to $26 from $13 at Roth Capital » 10:08
07/14/20
07/14
10:08
07/14/20
10:08
INMB

INmune Bio

$13.75 /

+5.01 (+57.32%)

Roth Capital analyst…

Roth Capital analyst Jonathan Aschoff raised the firm's price target on INmune Bio to $26 from $13 and keeps a Buy rating on the shares after interim results from a Phase 1b trial demonstrated that Xpro1595 can reduce neuroinflammation in patients with Alzheimer's disease. The analyst, who said he is "highly encouraged" by the extent of neuroinflammation reduction as measured by change in white matter free water via MRI, cautioned investors that "it is still too early to make sweeping conclusions about likely cognitive improvements in the overall AD population."

ShowHide Related Items >><<
INMB INmune Bio
$13.75 /

+5.01 (+57.32%)

INMB INmune Bio
$13.75 /

+5.01 (+57.32%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
INMB INmune Bio
$13.75 /

+5.01 (+57.32%)

INMB INmune Bio
$13.75 /

+5.01 (+57.32%)

On The Fly
Fly Intel: Pre-market Movers » 09:02
07/14/20
07/14
09:02
07/14/20
09:02
KPTI

Karyopharm

$17.83 /

-1.33 (-6.94%)

, TSLA

Tesla

$1,493.85 /

-53.69 (-3.47%)

, FIT

Fitbit

$6.64 /

-0.175 (-2.57%)

, HBI

Hanesbrands

$11.47 /

+0.035 (+0.31%)

, INMB

INmune Bio

$8.74 /

+1.72 (+24.50%)

, EQ

Equillium

$27.05 /

+23.95 (+772.58%)

, VRCA

Verrica Pharmaceuticals

$8.80 /

-0.71 (-7.47%)

, SPOT

Spotify

$261.11 /

-17.08 (-6.14%)

, OSMT

Osmotica Pharmaceuticals

$7.71 /

-1.06 (-12.09%)

, JPM

JPMorgan

$97.66 /

+1.35 (+1.40%)

, C

Citi

$52.25 /

-0.39 (-0.74%)

, WFC

Wells Fargo

$25.43 /

-0.04 (-0.16%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

VRCA Verrica Pharmaceuticals
$8.80 /

-0.71 (-7.47%)

TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

SPOT Spotify
$261.11 /

-17.08 (-6.14%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

KPTI Karyopharm
$17.83 /

-1.33 (-6.94%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

HBI Hanesbrands
$11.47 /

+0.035 (+0.31%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

EQ Equillium
$27.05 /

+23.95 (+772.58%)

C Citi
$52.25 /

-0.39 (-0.74%)

KPTI Karyopharm
$17.83 /

-1.33 (-6.94%)

07/01/20 Morgan Stanley
Karyopharm initiated with an Overweight at Morgan Stanley
06/23/20 JPMorgan
Karyopharm price target raised to $37 from $31 at JPMorgan
06/23/20 RBC Capital
Karyopharm price target raised to $30 from $28 at RBC Capital
05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

07/14/20 Piper Sandler
Tesla price target raised to $2,322 from $939 at Piper Sandler
07/13/20
Fly Intel: Top five analyst upgrades
07/13/20 Morgan Stanley
Morgan Stanley says Tesla's 'virtually unchallenged dominance' may be near end
07/13/20 Roth Capital
Tesla upgraded to Neutral at Roth Capital as Musk prepares Indian market entry
FIT Fitbit
$6.64 /

-0.175 (-2.57%)

06/19/20 Deutsche Bank
Fitbit acquisition completing remains base case at Deutsche Bank
11/27/19 Deutsche Bank
Second Fitbit suitor should limit downside if deal breaks, says Deutsche Bank
11/06/19 DA Davidson
Sonos rallies after DA Davidson calls 'natural acquisition target' for Apple
11/04/19 DA Davidson
Fitbit downgraded to Neutral from Buy at DA Davidson
HBI Hanesbrands
$11.47 /

+0.035 (+0.31%)

07/14/20 Credit Suisse
Hanesbrands upgraded to Outperform from Neutral at Credit Suisse
07/14/20 Credit Suisse
Hanesbrands upgraded to Outperform from Neutral at Credit Suisse
06/24/20 B. Riley FBR
Hanesbrands products largely sold out at Walmart and Target, says B. Riley FBR
04/01/20
Fly Intel: Top five analyst initiations
INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
EQ Equillium
$27.05 /

+23.95 (+772.58%)

07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
VRCA Verrica Pharmaceuticals
$8.80 /

-0.71 (-7.47%)

06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
06/24/20 Northland
Verrica Pharmaceuticals initiated with an Outperform at Northland
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
SPOT Spotify
$261.11 /

-17.08 (-6.14%)

07/14/20 UBS
Spotify double-downgraded to Sell from Buy at UBS
07/14/20 UBS
Spotify downgraded to Sell from Buy at UBS
07/13/20 BofA
Spotify price target raised to $357 from $185 at BofA
07/06/20
Fly Intel: Top five analyst downgrades
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

07/10/20 Truist
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

07/09/20 Wolfe Research
JPMorgan upgraded to Outperform from Peer Perform at Wolfe Research
07/09/20 DA Davidson
JPMorgan upgraded to Buy from Neutral at DA Davidson
07/08/20 Seaport Global
JPMorgan initiated with a Buy at Seaport Global
06/23/20 Wells Fargo
Finicity should help MasterCard with open banking efforts, says Wells Fargo
C Citi
$52.25 /

-0.39 (-0.74%)

07/08/20 Seaport Global
Citi initiated with a Buy at Seaport Global
07/07/20 Societe Generale
Societe Generale upgrades BofA, Citi to Buy on 'path to respectability'
07/07/20 Societe Generale
Citi upgraded to Buy from Hold at Societe Generale
07/01/20 BofA
BofA makes 14 additions, four deletions from US 1 list
WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

07/10/20 Baird
Wells Fargo upgraded to Outperform from Neutral at Baird
07/09/20 Wolfe Research
Wells Fargo upgraded to Peer Perform from Underperform at Wolfe Research
07/08/20 JPMorgan
Wells Fargo price target lowered to $29.50 from $32 at JPMorgan
07/08/20 Seaport Global
Wells Fargo initiated with a Neutral at Seaport Global
WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

VRCA Verrica Pharmaceuticals
$8.80 /

-0.71 (-7.47%)

TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

SPOT Spotify
$261.11 /

-17.08 (-6.14%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

KPTI Karyopharm
$17.83 /

-1.33 (-6.94%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

HBI Hanesbrands
$11.47 /

+0.035 (+0.31%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

EQ Equillium
$27.05 /

+23.95 (+772.58%)

C Citi
$52.25 /

-0.39 (-0.74%)

  • 14
    Jul
  • 04
    Mar
  • 14
    Feb
  • 09
    Jan
WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

SPOT Spotify
$261.11 /

-17.08 (-6.14%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

C Citi
$52.25 /

-0.39 (-0.74%)

WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

VRCA Verrica Pharmaceuticals
$8.80 /

-0.71 (-7.47%)

TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

SPOT Spotify
$261.11 /

-17.08 (-6.14%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

KPTI Karyopharm
$17.83 /

-1.33 (-6.94%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

HBI Hanesbrands
$11.47 /

+0.035 (+0.31%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

SPOT Spotify
$261.11 /

-17.08 (-6.14%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

HBI Hanesbrands
$11.47 /

+0.035 (+0.31%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

C Citi
$52.25 /

-0.39 (-0.74%)

TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

On The Fly
Fly Intel: After-Hours Movers » 18:58
07/13/20
07/13
18:58
07/13/20
18:58
INMB

INmune Bio

$8.74 /

+1.72 (+24.50%)

, VNDA

Vanda Pharmaceuticals

$11.37 /

-0.125 (-1.09%)

, FREQ

Frequency Therapeutics

$20.43 /

-2.4 (-10.51%)

, EW

Edwards Lifesciences

$67.18 /

-0.67 (-0.99%)

, BA

Boeing

$175.62 /

-2.825 (-1.58%)

, OSMT

Osmotica Pharmaceuticals

$7.71 /

-1.06 (-12.09%)

, ALT

Altimmune

$24.88 /

+2.56 (+11.47%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

06/09/20 Citi
Vanda downgraded to Neutral on FDA dispute at Citi
06/09/20 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
03/16/20
Fly Intel: Top five analyst downgrades
03/16/20 Oppenheimer
Vanda Pharmaceuticals downgraded to Underperform at Oppenheimer on Hetlioz risks
FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

06/05/20 Piper Sandler
Post points to Edwards resuming recruiting for CLASP trial, says Piper Sandler
04/28/20 Wells Fargo
Edwards Lifesciences downgraded on sales growth gap at Wells Fargo
04/28/20 Wells Fargo
Edwards Lifesciences downgraded to Equal Weight from Overweight at Wells Fargo
04/27/20 Barclays
Edwards Lifesciences price target lowered to $155 from $165 at Barclays
BA Boeing
$175.62 /

-2.825 (-1.58%)

07/09/20
Emirates tells Bloomberg Boeing 777X likely to miss 2021 debut
07/08/20 Bernstein
Bernstein downgrades Spirit AeroSystems on slower delivery recovery
06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

07/10/20 Truist
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
ALT Altimmune
$24.88 /

+2.56 (+11.47%)

06/01/20 Roth Capital
Altimmune surprises with differentiated T-COVID study, says Roth Capital
05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

  • 14
    Jul
  • 14
    Jul
  • 09
    Jan
  • 03
    Oct
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

Hot Stocks
INmune Bio announces interim phase 1B data on XPro1595 in Alzheimer's » 16:18
07/13/20
07/13
16:18
07/13/20
16:18
INMB

INmune Bio

$8.74 /

+1.72 (+24.50%)

INmune Bio reported…

INmune Bio reported clinical data demonstrating that its lead drug candidate, XPro1595, decreases neuroinflammation in patients with Alzheimer's disease. Interim results from a Phase Ib clinical trial show that treatment with XPro1595 decreases white matter free water, a biomarker of neuroinflammation measured by MRI. XPro1595 is a next-generation inhibitor of tumor necrosis factor that selectively neutralizes soluble TNF, an inflammatory cytokine implicated in Alzheimer's pathology, without affecting transmembrane TNF or the TNF receptors. Specifically, INmune compared biomarker data obtained from six patients treated with XPro1595 for 12 weeks with data from 25 Alzheimer's patients from the Alzheimer's Disease Neuroimaging Initiative that are part of a natural history database in patients with Alzheimer's. Over a 12-week period, whole brain inflammation increased by 5.1% in the ADNI patients compared to an increase of 1.7% and a decrease of 2.3% in patients treated weekly with 0.3mg/kg or 1.0mg/kg of XPro1595, respectively. A more detailed analysis revealed a 40.6% reduction in neuroinflammation in the Arcuate Fasciculus in patients treated with XPro1595. By contrast, the ADNI cohort had a 4.6% increase in Arcuate Fasciculus neuroinflammation.

ShowHide Related Items >><<
INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

Over a month ago
Hot Stocks
INmune Bio receives regulatory approval to initiate Phase 1 trial of INKmune » 09:01
06/11/20
06/11
09:01
06/11/20
09:01
INMB

INmune Bio

$5.55 /

-0.05 (-0.89%)

INmune Bio announced that…

INmune Bio announced that the Medicines and Healthcare products Regulatory Agency has given approval to initiate a Phase I clinical trial of INKmune, a novel therapy to prime the patient's own NK cells to attack their cancer, in patients with high-risk Myelodysplastic Syndrome. This single center Phase I trial will be the first-in-man study using INKmune. Based on the current environment and timetable of its clinical site, INmune Bio is targeting the study initiation in the 2nd half of this year.

ShowHide Related Items >><<
INMB INmune Bio
$5.55 /

-0.05 (-0.89%)

INMB INmune Bio
$5.55 /

-0.05 (-0.89%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
INMB INmune Bio
$5.55 /

-0.05 (-0.89%)

Hot Stocks
INmune Bio announces publication of review of innate immune cell potential » 09:08
05/19/20
05/19
09:08
05/19/20
09:08
INMB

INmune Bio

$5.53 /

-0.04 (-0.72%)

INmune Bio announced…

INmune Bio announced publication of a review article: Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer in the journal Stem Cells Translational Medicine by May Sabry, PhD and Professor Mark Lowdell, PhD, co-founder and Chief Scientific Officer of INmune Bio, past vice-president (Europe) of the International Society of Cell & Gene Therapy and faculty professor at University College London. The article reviews the potential of harnessing cells of the innate immune system to treat cancer. This publication is one of the first to comprehensively review clinical trials of the common innate immune effector cells. It highlights the breadth of innate immunotherapy options and the global interest in harnessing this side of the immune system. Prof. Lowdell has been a leader in identifying how cancer evades innate immune surveillance by NK cells and how to overcome those resistance mechanisms to allow NK cells to attack the tumor.

ShowHide Related Items >><<
INMB INmune Bio
$5.53 /

-0.04 (-0.72%)

INMB INmune Bio
$5.53 /

-0.04 (-0.72%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
INMB INmune Bio
$5.53 /

-0.04 (-0.72%)

Hot Stocks
INmune Bio announces upcoming milestones » 09:08
05/14/20
05/14
09:08
05/14/20
09:08
INMB

INmune Bio

$4.80 /

-0.67 (-12.25%)

Report results of Phase 1…

Report results of Phase 1 XPro1595 in Alzheimer's Disease, expected to complete 2H 2020. Submit IND for Quellor for the prevention of complications of COVID-19 infection, expected in May 2020. Enroll first patient in Phase II Quellor program, targeting COVID-19 patients with complications from COVID19 as soon as possible. The following milestone timelines have been updated due to the ongoing COVID-19 pandemic. Enroll first patient in Phase II INB03 program, targeting trastuzumab resistant HER2+ breast cancer using INB03 as part of combination therapy, expected mid-2021. Enroll first patient in Phase II LIVNate for NASH, expected mid-2021. Enroll first patient in Phase I INKmune in High Risk MDS cancer, expected 2H20. Enroll first patient in Phase I INKmune in Ovarian cancer, expected mid-2021.

ShowHide Related Items >><<
INMB INmune Bio
$4.80 /

-0.67 (-12.25%)

INMB INmune Bio
$4.80 /

-0.67 (-12.25%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
INMB INmune Bio
$4.80 /

-0.67 (-12.25%)

Hot Stocks
INmune Bio on track to report data in XPro1595 Phase 1 study in October  09:07
05/14/20
05/14
09:07
05/14/20
09:07
INMB

INmune Bio

$4.80 /

-0.67 (-12.25%)

 
ShowHide Related Items >><<
INMB INmune Bio
$4.80 /

-0.67 (-12.25%)

INMB INmune Bio
$4.80 /

-0.67 (-12.25%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
INMB INmune Bio
$4.80 /

-0.67 (-12.25%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.